Pharmacokinetics, Safety and Efficacy Study of GP30341 (GEROPHARM, Russia)

NACompletedINTERVENTIONAL
Enrollment

246

Participants

Timeline

Start Date

March 17, 2022

Primary Completion Date

May 11, 2022

Study Completion Date

July 20, 2022

Conditions
PharmacokineticsSafety IssuesEfficacy
Interventions
DRUG

GP30341 capsules 200 mg

orall take of capsules twice a day

DRUG

Standard therapy

Standard medicines for treatment of a new coronavirus infection 2019 (COVID-19).

Trial Locations (5)

150007

"Yaroslavl Region Clinical Hospital No. 3, ,, Mayakovskogo st., 61", Yaroslavl

195427

"St. Petersburg State Health Institution City Polyclinic No. 112", Saint Petersburg

236005

"Kaliningrad State Healthcare Institution Central City Clinical Hospital", Kaliningrad

390026

Federal Ryazan State Medical University named after Academician I.P. Pavlov, Ryazan

630007

Novosibirsk Federal State Medical University, Novosibirsk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Geropharm

INDUSTRY